GSK3B and Stroke: Additionally, TWS119 enhanced the level of β-catenin via inhibiting GSK-3β at day 14 after stroke and mitigated the histological damage of focal cerebral ischemic mouse at day 21 after stroke (see Supplementary Figure 2S, Additional file 1).